U.S. Markets closed

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
376.35+5.31 (+1.43%)
At close: 4:00PM EST

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500

IndustryDiagnostics & Research
Full Time Employees7,700

Key Executives

NameTitlePayExercisedYear Born
Mr. Francis A. deSouzaCEO, Pres & DirectorN/AN/A1971
Mr. Sam A. SamadCFO & Sr. VP626.7kN/A1970
Dr. Joydeep GoswamiSr. VP of Corp. Devel. & Strategic Planning384.38kN/A1971
Ms. Aimee L. HoytChief People Officer & Sr. VP864.07kN/A1971
Mr. Robert P. RagusaSr. VP of Global Quality & OperationsN/AN/A1960
Ms. Karen K. McGinnisVP & Chief Accounting OfficerN/AN/A1967
Dr. Alexander Aravanis M.D., Ph.D.Sr. VP & Chief Technology OfficerN/AN/AN/A
Mr. Steve PhillpottSr. VP & Chief Information OfficerN/AN/AN/A
Ms. Juliet CunninghamVP of Investor RelationsN/AN/AN/A
Mr. Charles E. DadswellSr. VP, Gen. Counsel & Sec.N/AN/A1959
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Illumina, Inc.’s ISS Governance QualityScore as of December 1, 2020 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.